This clinical trial is focused on studying a type of cancer called low-grade endometrial stromal sarcoma, which is a rare form of cancer that affects the lining of the uterus. The study is investigating the effects of stopping versus continuing treatment with medications known as aromatase inhibitors. These medications include Anastrozole (also known as Arimidex), Letrozole, and Exemestane (also known as Aromasin). Aromatase inhibitors are used to lower estrogen levels in the body, which can help slow the growth of certain types of cancer cells.

The purpose of the study is to compare the outcomes of patients who continue taking aromatase inhibitors with those who stop taking them. Participants in the study will be randomly assigned to either continue their current treatment or to stop it. The study will monitor the progression of the disease over time to see if there is a difference in how long patients remain free from cancer growth. This is known as progression-free survival. The study will also look at other factors such as overall survival, safety, quality of life, and the time until further treatment is needed.

Participants will be involved in the study for a period of time, during which they will receive regular check-ups and assessments to monitor their health and the status of their cancer. The study aims to provide valuable information on the best approach to managing low-grade endometrial stromal sarcoma with aromatase inhibitors, potentially improving treatment strategies for patients with this condition.